Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO):study protocol for a randomized controlled trial
BACKGROUND: Current guidelines recommend that patients with Staphylococcus aureus bloodstream infection (SAB) are treated with long courses of intravenous antimicrobial therapy. This serves to avoid SAB-related complications such as relapses, local extension and distant metastatic foci. However, in certain clinical scenarios, the incidence of SAB-related complications is low. Patients with a low-risk for complications may thus benefit from an early switch to oral medication through earlier discharge and fewer complications of intravenous therapy. The major objective for the SABATO trial is to... Mehr ...
Verfasser: |
Kaasch, Achim J
Fätkenheuer, Gerd
Prinz-Langenohl, Reinhild
Paulus, Ursula
Hellmich, Martin
Weiß, Verena
Jung, Norma
Rieg, Siegbert
Kern, Winfried V
Seifert, Harald |
Dokumenttyp: |
Artikel |
Erscheinungsdatum: |
2015 |
Reihe/Periodikum: |
Kaasch , A J , Fätkenheuer , G , Prinz-Langenohl , R , Paulus , U , Hellmich , M , Weiß , V , Jung , N , Rieg , S , Kern , W V , Seifert , H & SABATO trial group (with linked authorship to the individuals in the Acknowledgements section) 2015 , ' Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO) : study protocol for a randomized controlled trial ' , Trials , vol. 16 , pp. 450 . https://doi.org/10.1186/s13063-015-0973-x |
Sprache: |
Englisch |
Permalink: |
https://search.fid-benelux.de/Record/base-29249010 |
Datenquelle: |
BASE;
Originalkatalog |
Powered By: |
BASE |
Link(s) :
|
https://hdl.handle.net/11370/ecfa0ad5-0688-4823-bb82-7046061a6344 |